NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it will collaborate with the Moffitt Cancer Center on the development of a microRNA-based diagnostic for thyroid neoplasia.

According to Rosetta, between four and seven percent of the general population develops thyroid nodules, but fewer than 10 percent of these are malignant. Fine needle aspiration (FNA) is routinely conducted to obtain tissue for biopsy, but analyses of these samples are often inconclusive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.